Basic guide to the mechanisms of antiestrogen action.

Forty years ago, Lerner and coworkers (1958) discovered the first nonsteroidal antiestrogen and Jensen (Jensen and Jacobson, 1960) identified a target for drug action, the ER. This knowledge opened the door for the clinical development of tamoxifen which we now know provides a survival advantage in both node-positive and node-negative patients with ER-positive disease (Early Breast Cancer Trialists Collaborative Group, 1992, 1998). The drug has been studied extensively, and the results have provided an invaluable insight into possible ancillary advantages of "antiestrogens", i.e., maintenance of bone density and the prevention of coronary heart disease, and possible disadvantages, i.e., rat liver carcinogenesis and an increased risk of endometrial cancer. Most importantly, the identification of the target site-specific actions of tamoxifen caused a paradigm shift in the prospective uses of antiestrogens from a direct exploitation of the antitumor properties to the broader application as a preventative for osteoporosis, but with the beneficial side effects of preventing breast and endometrial cancer. Raloxifene, a second-generation SERM, has all the properties in the laboratory that would encourage development as a safe preventative for osteoporosis (Jordan et al., 1997). As a result, raloxifene has been evaluated in more than 11,000 postmenopausal women and found to maintain bone density with significant decreases in breast cancer incidence and no increase in endometrial thickness. Raloxifene is now available as a preventative for osteoporosis in postmenopausal women. There is every reason to believe that a multifaceted agent like raloxifene will find widespread use, and there will be continuing interest by the pharmaceutical industry in the development of new agents with even broader applications. The extensive clinical effort is augmented by past molecular innovations in the laboratory and the future promise of new discoveries. The cloning and sequencing of the ER (Green et al., 1986; Greene et al., 1986) has allowed the development of an ER knock-out mouse (Lubahn et al., 1993) that compliments Jensen's pioneering work (Jensen and Jacobson, 1962) and describes the consequences of the loss of ER alpha. However, ER beta (Kuiper et al., 1996), the second ER, has provided an additional dimension to the description of estrogen and antiestrogen action. For the future, the development of ER beta monoclonal antibodies, the classification of target sites for the protein around the body, and the creation of ER beta and ER alpha, beta knock-out mice will identify new therapeutic targets to modulate physiological functions. Clearly, the successful crystallization of ER alpha with raloxifene (Brzozowski et al., 1997) must act as a stimulus for the crystallization of ER beta. The central issue for research on antiestrogen pharmacology is the discovery of the mechanism (or mechanisms) of target site-specificity for the modulation of estrogenic and antiestrogenic response. The description of a stimulatory pathway for antiestrogens through an AP-1 ER beta signal transduction pathway (Paech et al., 1997), although interesting, may not entirely explain the estrogenicity of antiestrogens. The model must encompass the sum of pharmacological consequences of signal transduction through ER alpha and ER beta with the simultaneous competition from endogenous estrogens at both sites. This is complicated because estradiol is an antagonist at ER beta through AP-1 sites (Paech et al., 1997), so this is clearly not the pathway for estrogen-induced bone maintenance in women. Estrogen is stimulatory through ER alpha, but antiestrogens are usually partial agonists and may either block or stimulate genes. However, we suggest that the ER alpha stimulatory pathway could be amplified through selective increases in coactivators. The principle is illustrated with the MDA-MB-231 cells stably transfected with the cDNAs for the wild-type and the amino acid 351 mutan

[1]  M. Dowsett,et al.  Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. , 1991, Cancer research.

[2]  V. Jordan,et al.  Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. , 1990, European journal of cancer.

[3]  M. Parker,et al.  Characterization of ligand-dependent phosphorylation of the estrogen receptor. , 1994, Molecular endocrinology.

[4]  C. Sonnenschein,et al.  p-Nonyl-phenol: an estrogenic xenobiotic released from "modified" polystyrene. , 1991, Environmental health perspectives.

[5]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[6]  R. Dickson,et al.  Growth factors in breast cancer. , 1995, Endocrine reviews.

[7]  V. Jordan,et al.  Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. , 1995, Anti-cancer drugs.

[8]  W. Jonat,et al.  Regulation and role of TGF beta production in breast cancer. , 1996, Annals of the New York Academy of Sciences.

[9]  S. Thorgeirsson,et al.  Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. , 1996, Carcinogenesis.

[10]  D. McDonnell,et al.  Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. , 1996, Molecular endocrinology.

[11]  B. O’Malley,et al.  CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Dijke,et al.  Regulation of the levels of three transforming growth factor β mRNAs by estrogen and their effects on the proliferation of human breast cancer cells , 1993, Molecular and Cellular Endocrinology.

[13]  L. Kangas,et al.  Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  K. Korach,et al.  Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[15]  I. Treilleux,et al.  A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers , 1997, Molecular and cellular biology.

[16]  S. Durani,et al.  Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. , 1990, Journal of Medicinal Chemistry.

[17]  J. Liehr,et al.  Induction of covalent DNA adducts in rodents by tamoxifen. , 1992, Cancer research.

[18]  A. Harris,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. , 1994, Biochemical pharmacology.

[19]  S. Rössner,et al.  Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. , 1984, Atherosclerosis.

[20]  P. Chambon,et al.  Functional domains of the human estrogen receptor , 1987, Cell.

[21]  J. Foekens,et al.  Transforming growth factor beta secretion from primary breast cancer fibroblasts , 1995, Molecular and Cellular Endocrinology.

[22]  S. Noguchi,et al.  Down‐regulation of transforming growth factor‐α by tamoxifen in human breast cancer , 1993 .

[23]  U. Eppenberger,et al.  No loss of estrogenic or anti‐estrogenic activity after demethylation of droloxifene (3‐OH‐Tamoxifen) , 1985, International journal of cancer.

[24]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[25]  E. Jensen,et al.  Binding of antiestrogens exposes an occult antigenic determinant in the human estrogen receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Willem,et al.  Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.

[27]  B. O’Malley,et al.  Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  B. O’Malley The steroid receptor superfamily: more excitement predicted for the future. , 1990, Molecular endocrinology.

[29]  S. Durani,et al.  Structure-activity relationship of antiestrogens. Studies on 2,3-diaryl-1-benzopyrans. , 1990, Journal of medicinal chemistry.

[30]  B. Katzenellenbogen,et al.  A new actor in the estrogen receptor drama--enter ER-beta. , 1997, Endocrinology.

[31]  I. Christensen,et al.  Cell cycle analysis of estrogen stimulated growth of the human breast cancer cell line, MCF-7. , 1986, European journal of cancer & clinical oncology.

[32]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[33]  B. Kramer,et al.  Potential role of tamoxifen in prevention of breast cancer. , 1991, Journal of the National Cancer Institute.

[34]  B. O’Malley,et al.  Enhancement of human estrogen receptor activity by SPT6: a potential coactivator. , 1995, Molecular endocrinology.

[35]  A. Howell,et al.  Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. , 1996, British Journal of Cancer.

[36]  J. Feyzi,et al.  Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. , 1994, Journal of the National Cancer Institute.

[37]  P. Lønning,et al.  Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. , 1992, Cancer research.

[38]  M. Astruc,et al.  Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. , 1995, Endocrinology.

[39]  D. Phillips,et al.  Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. , 1996, Carcinogenesis.

[40]  P. Beaune,et al.  Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.

[41]  B. Katzenellenbogen,et al.  Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. , 1989, The Journal of biological chemistry.

[42]  D. Feldman,et al.  Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. , 1993, Endocrinology.

[43]  J. Gorski,et al.  Hormone receptors: studies on the interaction of estrogen with the uterus. , 1968, Recent progress in hormone research.

[44]  J. Pink,et al.  A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. , 1996, Nucleic acids research.

[45]  R. Weigel,et al.  Transcriptional regulation of estrogen receptor in breast carcinomas , 1995, Molecular and cellular biology.

[46]  Y. Dragan,et al.  The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis. , 1996, Carcinogenesis.

[47]  M. Harper,et al.  Mode of action of I.C.I. 46,474 in preventing implantation in rats. , 1967, Journal of Endocrinology.

[48]  D. Wolf,et al.  An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[49]  J H Lamb,et al.  A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. , 1994, Carcinogenesis.

[50]  T. Willson,et al.  Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. , 1997, Endocrinology.

[51]  M Jarman,et al.  Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length. , 1996, Journal of medicinal chemistry.

[52]  J. Cuzick,et al.  TAMOXIFEN AND CONTRALATERAL BREAST CANCER , 1985, The Lancet.

[53]  R. Sutherland,et al.  Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[54]  J. Swenberg Clinical relevance of laboratory and animal data on tamoxifen. , 1997, Oncology.

[55]  J. A. Hamilton,et al.  Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. , 1993, Molecular and cellular biology.

[56]  A. Bitonti,et al.  Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[57]  P. Chambon,et al.  The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function , 1988, Cell.

[58]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[59]  V. Jordan What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? A personal perspective. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  E. Dodds,et al.  A Simple Aromatic (Œstrogenic Agent with an Activity of the Same Order as that of Œstrone , 1937, Nature.

[61]  H. Koyama,et al.  Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. , 1993, Cancer.

[62]  S. Hilsenbeck,et al.  Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.

[63]  V. Jordan,et al.  Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. , 1990, Cancer research.

[64]  B. Katzenellenbogen,et al.  ANTIESTROGEN BASICITY‐ACTIVITY RELATIONSHIPS: A COMPARISON OF THE ESTROGEN RECEPTOR BINDING AND ANTIUTEROTROPHIC POTENCIES OF SEVERAL ANALOGS OF (Z)‐1,2‐DIPHENYL‐1‐(4‐(2‐(DIMETHYLAMINO)ETHOXY)PHENYL)‐1‐BUTENE (TAMOXIFEN, NOLVADEX) HAVING ALTERED BASICITY , 1982 .

[65]  M. Lippman,et al.  Growth of a human breast cancer cell line in serum-free hormone-supplemented medium. , 1978, Cancer research.

[66]  B. Katzenellenbogen,et al.  Antiestrogens: Mechanisms and actions in target cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[67]  W. McGuire Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.

[68]  Y. Sugimoto,et al.  TAT-59, a new triphenylethylene derivative with antitumor activity against hormone-dependent tumors. , 1990, European journal of cancer.

[69]  E. Borden,et al.  Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. , 1989, Cancer research.

[70]  D. Vorojeikina,et al.  Phosphorylation of Tyrosine 537 on the Human Estrogen Receptor Is Required for Binding to an Estrogen Response Element (*) , 1995, The Journal of Biological Chemistry.

[71]  U. Eppenberger,et al.  Inhibition of growth‐factor‐activated proliferation by anti‐estrogens and effects on early gene expression of mcf‐7 cells , 1993, International journal of cancer.

[72]  B. Katzenellenbogen,et al.  Biological potency and uterine estrogen receptor interactions of the metabolites of the antiestrogens CI628 and U23,469. , 1981, Endocrinology.

[73]  D. Phillips,et al.  Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. , 1996, Cancer research.

[74]  R. Turner,et al.  Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats. , 1988, Endocrinology.

[75]  A. Glasebrook,et al.  Correction: Raloxifene Response Needs More Than an Element , 1997, Science.

[76]  F. Alexander,et al.  Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial , 1995, BMJ.

[77]  W. Jonat,et al.  Transforming Growth Factor β2 (TGF-β2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen , 1995 .

[78]  A. Friedl,et al.  Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. , 1993, European journal of cancer.

[79]  J. Pink,et al.  Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. , 1990, Cancer research.

[80]  M. Lippman,et al.  Antiestrogenic effects of LY 117018 in MCF-7 cells. , 1983, Endocrinology.

[81]  R. Gray,et al.  Tamoxifen versus placebo: double-blind adjuvant trial in elderly women with stage II breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.

[82]  M. Dowsett,et al.  The novel anti-oestrogen idoxifene inhibits the growth of human MCF-7 breast cancer xenografts and reduces the frequency of acquired anti-oestrogen resistance. , 1997, British Journal of Cancer.

[83]  P. Chambon,et al.  Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes. , 1990, The Journal of biological chemistry.

[84]  John W. R. Schwabe,et al.  The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements , 1993, Cell.

[85]  R. Prentice,et al.  Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. , 1991, Preventive medicine.

[86]  P. Schwartz,et al.  High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  J. Gorski,et al.  An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. , 1983, The Journal of biological chemistry.

[88]  G. Williams,et al.  Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. , 1993, Cancer research.

[89]  J. Gorski,et al.  A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[90]  C. McDonald,et al.  Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. , 1991, BMJ.

[91]  I. White,et al.  Induction of CYP2B1 and 3A1, and associated monoxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. , 1993, Biochemical pharmacology.

[92]  J. Gustafsson,et al.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.

[93]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[94]  R. Turner,et al.  Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[95]  V. Jordan,et al.  Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. , 1991, Journal of the National Cancer Institute.

[96]  V. Jordan,et al.  Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[97]  D. Wheeler,et al.  Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells. , 1994, Molecular endocrinology.

[98]  N. Webster,et al.  The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.

[99]  P. Lønning,et al.  Determination of Droloxifene and Two Metabolites in Serum by High‐Pressure Liquid Chromatography , 1995, Therapeutic drug monitoring.

[100]  C. Osborne,et al.  Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.

[101]  S. Robinson,et al.  Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse. , 1989, Cancer research.

[102]  M. Lippman,et al.  Oestrogen-responsive human breast cancer in long term tissue culture , 1975, Nature.

[103]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[104]  E. Baulieu,et al.  Structural differences between the hormone and antihormone estrogen receptor complexes bound to the hormone response element. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[105]  V. Jordan,et al.  Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. , 1995, Cancer letters.

[106]  J. Styles,et al.  Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. , 1994, Carcinogenesis.

[107]  B. Furr,et al.  The pharmacology and clinical uses of tamoxifen. , 1984, Pharmacology & therapeutics.

[108]  V. Jordan,et al.  The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. , 1998, British Journal of Cancer.

[109]  M. Parker,et al.  Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[110]  E. Siris,et al.  Effects of tamoxifen on spinal bone density in women with breast cancer. , 1989, Journal of the National Cancer Institute.

[111]  A. Howell,et al.  Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[112]  R. Noble,et al.  BIOLOGICAL EFFECTS OF THE SYNTHETIC ŒSTROGENIC SUBSTANCE 4 : 4'-DIHYDROXY-α : β-DIETHYLSTILBENE , 1938 .

[113]  V. Jordan,et al.  Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast. , 1988, Critical reviews in clinical laboratory sciences.

[114]  P. Argos,et al.  Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A , 1986, Nature.

[115]  M. Dowsett,et al.  Idoxifene: report of a phase I study in patients with metastatic breast cancer. , 1995, Cancer research.

[116]  L. Lerner,et al.  A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. , 1958, Endocrinology.

[117]  G. Beatson On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[118]  V. Jordan,et al.  Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. , 1987, Cancer research.

[119]  V. Jordan Long-Term Tamoxifen Treatment for Breast Cancer , 1994 .

[120]  M. Thompson,et al.  Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. , 1960, The Journal of biological chemistry.

[121]  B. Katzenellenbogen,et al.  Interaction of a high affinity anti-estrogen (alpha-[4-pyrrolidinoethoxy]phenyl-4-hydroxy-alpha'-nitrostilbene, CI628M) with uterine estrogen receptors. , 1981, The Journal of biological chemistry.

[122]  J. Kemp,et al.  The metabolism of tamoxifen in human. , 1979, Biochemical Pharmacology.

[123]  D. Phillips,et al.  Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. , 1996, Carcinogenesis.

[124]  V. Jordan A current view of tamoxifen for the treatment and prevention of breast cancer , 1993 .

[125]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[126]  J. Kemp,et al.  Identification and biological activity of tamoxifen metabolites in human serum. , 1983, Biochemical pharmacology.

[127]  C. Redmond,et al.  Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. , 1995, Journal of the National Cancer Institute.

[128]  V. Jordan 243. Antitumour activity of the antiestrogen ICI 46,474 (Tamoxifen) in the dimethylbenzanthracene (DMBA)—induced rat mammary carcinoma model , 1974 .

[129]  J. Pink,et al.  Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line. , 1997, British Journal of Cancer.

[130]  B. Katzenellenbogen,et al.  Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. , 1994, Molecular endocrinology.

[131]  K.,et al.  A new derivative of triphenylethylene: effect on implantation and mode of action in rats. , 1967, Journal of reproduction and fertility.

[132]  C. Arnaud,et al.  A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[133]  P. Grimes,et al.  Triparanol-induced Cataract in Rats. , 1963, Transactions of the American Ophthalmological Society.

[134]  P. Chambon,et al.  Modulation of transcriptional activation by ligand‐dependent phosphorylation of the human oestrogen receptor A/B region. , 1993, The EMBO journal.

[135]  B. Moorthy,et al.  Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. , 1994, Carcinogenesis.

[136]  V. Jordan,et al.  Gynecologic effects of tamoxifen and the association with endometrial carcinoma , 1995, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[137]  V. Jordan,et al.  Oestrogenic and antioestrogenic actions in a series of triphenylbut‐1‐enes: modulation of prolactin synthesis in vitro , 1986, British journal of pharmacology.

[138]  V. Jordan Alternate antiestrogens and approaches to the prevention of breast cancer , 1995, Journal of cellular biochemistry. Supplement.

[139]  J. Boyle,et al.  Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. , 1993, Genomics.

[140]  W. Gradishar,et al.  Clinical potential of new antiestrogens. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  B. Katzenellenbogen,et al.  Differential regulation of gene expression by estrogen in estrogen growth-independent and -dependent MCF-7 human breast cancer cell sublines. , 1991, Molecular endocrinology.

[142]  K. Pritchard,et al.  Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. , 1986, Cancer research.

[143]  Preliminary Analysis by the Crc Adjuvant Breast Trial Working Party Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party. , 1988, British Journal of Cancer.

[144]  Myles Brown,et al.  Polarity-specific activities of retinoic acid receptors determined by a co-repressor , 1995, Nature.

[145]  C. Osborne,et al.  Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. , 1987, European journal of cancer & clinical oncology.

[146]  R. Derynck,et al.  Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells , 1987, Cell.

[147]  M. Ahotupa,et al.  Tamoxifen induces hepatocellular carcinoma in rat liver , 1990 .

[148]  S. Durani,et al.  Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans. , 1990, Journal of medicinal chemistry.

[149]  J. Benson,et al.  Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. , 1997, British Journal of Cancer.

[150]  V. Jordan,et al.  Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. , 1987, Cancer research.

[151]  G. Duncan,et al.  Mammalian antifertility agents. 3. 1-Aryl-2-phenyl-1,2,3,4-tetrahydro-1-naphthols, 1-aryl-2-phenyl-3,4-dihydronaphthalenes, and their derivatives. , 1966, Journal of medicinal chemistry.

[152]  R. Sutherland,et al.  Oestrogen receptor gene structure and function in breast cancer , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[153]  J. Robertson,et al.  Oestrogen receptor: a stable phenotype in breast cancer. , 1996, British Journal of Cancer.

[154]  Gerhart U. Ryffel,et al.  An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells , 1986, Cell.

[155]  B. Katzenellenbogen,et al.  Lipophilic impurities, not phenolsulfonphthalein, account for the estrogenic activity in commercial preparations of phenol red. , 1988, Journal of steroid biochemistry.

[156]  R. Prescott,et al.  Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. , 1996, British Journal of Cancer.

[157]  D. Phillips,et al.  Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats. , 1994, Carcinogenesis.

[158]  R. Smith,et al.  Induction of ovulation with clomiphene citrate. , 1977, Minnesota medicine.

[159]  V. Jordan Tamoxifen: the herald of a new era of preventive therapeutics. , 1997, Journal of the National Cancer Institute.

[160]  A. Howell,et al.  Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer , 1995, The Lancet.

[161]  J. Pink,et al.  Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. , 1996, Cancer research.

[162]  V. Jordan,et al.  Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure. , 1984, Molecular pharmacology.

[163]  G. Greene,et al.  Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells , 1984, Nature.

[164]  C. D. Jones,et al.  Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal in , 1984, Journal of medicinal chemistry.

[165]  R. Clarke,et al.  The effects of a constitutive expression of transforming growth factor-alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo. , 1989, Molecular endocrinology.

[166]  J. Katzenellenbogen,et al.  Bis(4-hydroxyphenyl)[2-(phenoxysulfonyl)phenyl]methane: isolation and structure elucidation of a novel estrogen from commercial preparations of phenol red (phenolsulfonphthalein) , 1988, Journal of medicinal chemistry.

[167]  A. Wakeling,et al.  Novel antioestrogens without partial agonist activity. , 1988, Journal of steroid biochemistry.

[168]  A. D. Schryver,et al.  Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1 , 1992 .

[169]  D. Kupfer,et al.  Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. , 1991, Cancer research.

[170]  B. Katzenellenbogen,et al.  Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. , 1992, The Journal of biological chemistry.

[171]  J. Avigan,et al.  EFFECTS OF TRIPARANOL (MER-29) ON CHOLESTEROL BIOSYNTHESIS AND ON BLOOD STEROL LEVELS IN MAN. , 1961, The Journal of clinical investigation.

[172]  V. Jordan,et al.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: Problems and potential for future clinical applications , 1983, Breast cancer research and treatment.

[173]  G. Rao Mode of entry of steroid and thyroid hormones into cells , 1981, Molecular and Cellular Endocrinology.

[174]  B. Katzenellenbogen,et al.  Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation. , 1992, The Journal of biological chemistry.

[175]  D. Heitjan,et al.  Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. , 1995, The Journal of clinical endocrinology and metabolism.

[176]  J. Cuzick,et al.  Long term effects of tamoxifen. Biological effects of Tamoxifen Working Party. , 1992, European journal of cancer.

[177]  S. Robinson,et al.  Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. , 1989, European journal of cancer & clinical oncology.

[178]  J. Gorski,et al.  Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. , 1983, The Journal of biological chemistry.

[179]  S. Cawthorn,et al.  Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group. , 1996, Journal of the National Cancer Institute.

[180]  V. Jordan,et al.  EVIDENCE FOR THE METABOLIC ACTIVATION OF NON‐STEROIDAL ANTIOESTROGENS: A STUDY OF STRUCTURE‐ACTIVITY RELATIONSHIPS , 1980, British journal of pharmacology.

[181]  J. Pink,et al.  An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. , 1995, Cancer research.

[182]  C. Klinge,et al.  Differential impact of flanking sequences on estradiol- vs 4-hydroxytamoxifen-liganded estrogen receptor binding to estrogen responsive element DNA , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[183]  K. Umesono,et al.  Determinants of target gene specificity for steroid/thyroid hormone receptors , 1989, Cell.

[184]  W. Jonat,et al.  Regulation and Role of TGFβ Production in Breast Cancer a , 1996 .

[185]  W. McGuire,et al.  Variant human breast tumor estrogen receptor with constitutive transcriptional activity. , 1991, Cancer research.

[186]  J. Pfeilschifter,et al.  Translocation of protein kinase C isoenzymes by elevated extracellular Ca2+ concentration in cells from a human giant cell tumor of bone. , 1995, Bone.

[187]  K. Hemminki,et al.  Tamoxifen-induced DNA adducts in leucocytes of breast cancer patients. , 1997, Carcinogenesis.

[188]  H. Sjöberg,et al.  Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[189]  W. Welshons,et al.  Estrogenic activity of phenol red , 1988, Molecular and Cellular Endocrinology.

[190]  H. Degani,et al.  A permanently charged tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents. , 1996, Cancer research.

[191]  P. Canney,et al.  CLINICAL SIGNIFICANCE OF TAMOXIFEN WITHDRAWAL RESPONSE , 1987, The Lancet.

[192]  J. Shine,et al.  Sequence and expression of human estrogen receptor complementary DNA. , 1986, Science.

[193]  R. Turner,et al.  Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. , 1996, Endocrinology.

[194]  V. Jordan,et al.  OESTROGENIC, ANTI‐OESTROGENIC AND FERTILITY EFFECTS OF SOME TRIPHENYLETHANES AND TRIPHENYLETHYLENES RELATED TO ETHAMOXYTRIPHETOL (MER 25) , 1976, British journal of pharmacology.

[195]  L. Black,et al.  Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. , 1980, Life sciences.

[196]  A. Dnistrian,et al.  Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[197]  E. Jensen,et al.  Estrogen receptors and breast cancer response to adrenalectomy. , 1971, National Cancer Institute monograph.

[198]  S. Robinson,et al.  The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure. , 1989, European journal of cancer & clinical oncology.

[199]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[200]  N. C. Misra,et al.  Centchroman—a non‐steroidal anti‐cancer agent for advanced breast cancer: Phase‐II study , 1989, International journal of cancer.

[201]  H. Pitot,et al.  Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. , 1995, Carcinogenesis.

[202]  F. Kern,et al.  Estrogen induction of TGF-α is mediated by an estrogen response element composed of two imperfect palindromes , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[203]  H. Mouridsen,et al.  Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[204]  V. Jordan Tamoxifen treatment for breast cancer: concept to gold standard. , 1997, Oncology.

[205]  Characterization of estrogen receptor variant mRNAs from human breast cancers. , 1992, Molecular endocrinology.

[206]  A Howell,et al.  Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  K. Korach,et al.  Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. , 1996, Recent progress in hormone research.

[208]  S. Shafie Erratum: Estrogen and the Growth of Breast Cancer: New Evidence Suggests Indirect Action , 1980, Science.

[209]  V. Jordan Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. , 1976, European journal of cancer.

[210]  G. Duncan,et al.  Mammalian antifertility agents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-tetrahydro-1-naphthols. , 1967, Journal of medicinal chemistry.

[211]  P. Brown,et al.  Activation and inhibition of the AP‐1 complex in human breast cancer cells , 1996, Molecular carcinogenesis.

[212]  P. Deininger,et al.  Identification of a New Subclass of Alu DNA Repeats Which Can Function as Estrogen Receptor-dependent Transcriptional Enhancers (*) , 1995, The Journal of Biological Chemistry.

[213]  C. Klinge,et al.  Footprint analysis of estrogen receptor binding to adjacent estrogen response elements , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[214]  H. Johansson,et al.  Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. , 1995, Journal of the National Cancer Institute.

[215]  S. Robinson,et al.  Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[216]  N. Weiss,et al.  Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. , 1995, Journal of the National Cancer Institute.

[217]  V. Jordan Tamoxifen and tumorigenicity: a predictable concern. , 1995, Journal of the National Cancer Institute.

[218]  S. Baylin,et al.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.

[219]  C. Slemenda,et al.  Dual‐energy X‐ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[220]  M. Montminy,et al.  Adaptor-mediated Recruitment of RNA Polymerase II to a Signal-dependent Activator (*) , 1996, The Journal of Biological Chemistry.

[221]  H. Gronemeyer,et al.  Transcription activation by estrogen and progesterone receptors. , 1991, Annual review of genetics.

[222]  T. Powles,et al.  32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. , 1995, Carcinogenesis.

[223]  B. Zondek,et al.  Phenol methyl ethers as oestrogenic agents. , 1938, The Biochemical journal.

[224]  M. Singh,et al.  Time-related effects of a triphenylethylene antiestrogen on estrogen-induced changes in uterine weight, estrogen receptors, and endometrial sensitivity in rats. , 1995, Contraception.

[225]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[226]  A. Neal,et al.  Does long-term administration of tamoxifen affect bone mineral density? , 1993, European journal of cancer.

[227]  P. Chambon,et al.  Oestradiol induction of a glucocorticoid-responsive gene by a chimaeric receptor , 1987, Nature.

[228]  D. Hayes,et al.  Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[229]  V. Jordan,et al.  The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. , 1998, Cancer research.

[230]  A. Haddow,et al.  Influence of Synthetic Oestrogens on Advanced Malignant Disease , 1944, British medical journal.

[231]  D. Wolf,et al.  Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. , 1993, Journal of the National Cancer Institute.

[232]  C. Labrie,et al.  Combined Effects of Dehydroepiandrosterone and EM-800 on Bone Mass, Serum Lipids, and the Development of Dimethylbenz(A)Anthracene-Induced Mammary Carcinoma in the Rat. , 1997, Endocrinology.

[233]  B. Katzenellenbogen,et al.  Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. , 1996, Molecular endocrinology.

[234]  F. Grantham,et al.  Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. , 1981, Journal of the National Cancer Institute.

[235]  R. Laughlin,et al.  Cataracts in patients treated with triparanol. , 1962, JAMA.

[236]  S. Chandrasekhar,et al.  Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate. , 1996, Bone.

[237]  N. Davidson Tamoxifen--panacea or Pandora's box? , 1992, The New England journal of medicine.

[238]  A. Parkinson,et al.  Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[239]  D. Edwards,et al.  Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. , 1992, The Journal of biological chemistry.

[240]  V. Jordan,et al.  Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. , 1988, Cancer research.

[241]  H. Huynh,et al.  Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. , 1993, Cancer research.

[242]  S. Fawell,et al.  Identification of two transactivation domains in the mouse oestrogen receptor. , 1989, Nucleic acids research.

[243]  Jordan Vc Tamoxifen treatment for breast cancer: Concept to gold standard , 1997 .

[244]  L. Black,et al.  Evidence for biological action of the antiestrogens LY117018 and tamoxifen by different mechanisms. , 1981, Endocrinology.

[245]  V. Jordan,et al.  Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. , 1983, Cancer research.

[246]  D. Williams,et al.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.

[247]  G. Greene,et al.  Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. , 1984, Cancer research.

[248]  I. Holdaway,et al.  Detection of contralateral breast cancer by mammography in women with previous breast cancer and the impact of endocrine therapy. , 1993, The New Zealand medical journal.

[249]  A. Wakeling,et al.  Effects of antioestrogens on the proliferation of MCF-7 human breast cancer cells. , 1989, Journal of molecular endocrinology.

[250]  E. Jensen,et al.  Estrogen-Receptor Interaction , 1973, Science.

[251]  Y. Ma,et al.  Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats. , 1995, Bone.

[252]  D. Tripathy,et al.  Tamoxifen for early breast cancer: An overview of the randomised trials , 1999 .

[253]  L. Wakefield,et al.  Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. , 1996, British Journal of Cancer.

[254]  D. Lewis,et al.  The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anti-carcinogenic/carcinogenic actions. , 1996, Carcinogenesis.

[255]  C. Christiansen,et al.  The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer , 1984, Cancer.

[256]  I. Christensen,et al.  Effects of the antioestrogen tamoxifen on the cell cycle kinetics of the human breast cancer cell line, MCF-7. , 1984, British Journal of Cancer.

[257]  V. Jordan,et al.  Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. , 1992, Journal of the National Cancer Institute.

[258]  N. Copeland,et al.  Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. , 1997, Molecular endocrinology.

[259]  P. Lønning,et al.  Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen , 2006, International journal of cancer.

[260]  Chawnshang Chang,et al.  An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol , 1992, Molecular and Cellular Endocrinology.

[261]  H. Storm,et al.  Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. , 1992, Acta oncologica.

[262]  Y. Ma,et al.  Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats. , 1995, Bone.

[263]  J. Gorski,et al.  Estrogen control of prolactin synthesis in vitro. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[264]  Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. , 1992, Molecular endocrinology.

[265]  C. Redmond,et al.  Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. , 1990, Journal of the National Cancer Institute.

[266]  G. Hortobagyi,et al.  Use of tamoxifen for breast cancer: twenty-eight years later. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[267]  V. Jordan Biochemical pharmacology of antiestrogen action. , 1984, Pharmacological reviews.

[268]  L. Lerner,et al.  Gonadotrophin Inhibiting and Anti-Fecundity Effects of Chloramiphene. ∗ , 1960, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[269]  C. Labrie,et al.  Long‐term inhibitory effects of a novel anti‐estrogen on the growth of ZR‐75‐1 and MCF‐7 human breast cancer tumors in nude mice , 1997, International journal of cancer.

[270]  C. Labrie,et al.  Comparative effects of 28‐day treatment with the new anti‐estrogen EM‐800 and tamoxifen on estrogen‐sensitive parameters in intact mice , 1997, International journal of cancer.

[271]  B. Rattel,et al.  Preclinical data for Droloxifene. , 1994, Cancer letters.

[272]  C. Osborne,et al.  Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells , 1988 .

[273]  Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. , 1996, Molecular endocrinology.

[274]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[275]  S. Venitt,et al.  Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. , 1994, Carcinogenesis.

[276]  K. Nose,et al.  Release of H2O2 and phosphorylation of 30 kilodalton proteins as early responses of cell cycle-dependent inhibition of DNA synthesis by transforming growth factor beta 1. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[277]  P. Chambon,et al.  Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. , 1990, Cancer research.

[278]  E. A. Doisy,et al.  An Ovarian Hormone: Preliminary Report on Its Localization, Extraction and Partial Purification, and Action in Test Animals , 1923 .

[279]  E. Wallach,et al.  Induction of ovulation with clomiphene citrate. , 1977, The Journal of reproductive medicine.

[280]  R. Robinson,et al.  Œstrogenic Activity of Certain Synthetic Compounds , 1938, Nature.

[281]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[282]  V. Jordan,et al.  Endocrine pharmacology of antiestrogens as antitumor agents. , 1990, Endocrine reviews.

[283]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[284]  P. Chambon,et al.  The human oestrogen receptor functions in yeast , 1988, Nature.

[285]  R. Barakat,et al.  Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. , 1994, Gynecologic oncology.

[286]  J. Waterton,et al.  Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. , 1992, The Journal of endocrinology.

[287]  A. Glasebrook,et al.  Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and Raloxifene , 1996, Science.

[288]  I W Taylor,et al.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. , 1983, Cancer research.

[289]  J. Sumpter,et al.  Environmentally persistent alkylphenolic compounds are estrogenic. , 1994, Endocrinology.

[290]  C. Klinge,et al.  Antiestrogen-liganded estrogen receptor interaction with estrogen responsive element DNA in vitro , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[291]  R. Winkelmann,et al.  Cataract formation after triparanol therapy. , 1962, Archives of ophthalmology.

[292]  S. Robinson,et al.  Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. , 1988, Journal of steroid biochemistry.

[293]  C. Labrie,et al.  Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat. , 1997, Endocrinology.

[294]  B. Katzenellenbogen,et al.  Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. , 1994, The Journal of biological chemistry.

[295]  C. Osborne,et al.  Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. , 1988, Cancer research.

[296]  M. Sunderland,et al.  Tamoxifen in premenopausal patients with metastatic breast cancer: a review. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[297]  L. Moore,et al.  3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. , 1994, Journal of medicinal chemistry.

[298]  Yee The insulin-like growth factor system as a target in breast cancer , 2022 .

[299]  K. Korach,et al.  Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. , 1995, Molecular endocrinology.

[300]  S. Robinson,et al.  Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model. , 1988, European journal of cancer & clinical oncology.

[301]  E. Jensen,et al.  A two-step mechanism for the interaction of estradiol with rat uterus. , 1968, Proceedings of the National Academy of Sciences of the United States of America.

[302]  D. Haller,et al.  Phase I study of toremifene in patients with advanced cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[303]  J. Devlin,et al.  Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. , 1989, Cancer research.

[304]  K. Grandien,et al.  Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .

[305]  J. Gorski,et al.  Nuclear localization of unoccupied oestrogen receptors , 1984, Nature.

[306]  H. Rochefort,et al.  Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. , 1990, Biochemical and biophysical research communications.

[307]  M. Carcangiu Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[308]  T. Powles,et al.  Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. , 1990, European journal of cancer.

[309]  R. Barakat Benign and hyperplastic endometrial changes associated with tamoxifen use. , 1997, Oncology.

[310]  P. Kelly,et al.  Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. , 1993, Bone and mineral.

[311]  J. Simard,et al.  Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. , 1997, Cancer research.

[312]  E. Dodds,et al.  Œstrogenic Activity of Anol; a Highly Active Phenol Isolated from the By-Products , 1938, Nature.

[313]  I. Weinstein,et al.  Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. , 1988, Cancer research.

[314]  W. Jonat,et al.  Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. , 1995, Cancer research.

[315]  L. Kèlland,et al.  Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. , 1994, British Journal of Cancer.

[316]  J. Pike,et al.  Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.

[317]  M. Jarman,et al.  A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. , 1994, Carcinogenesis.

[318]  C. Osborne,et al.  Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. , 1984, Cancer research.

[319]  P. Neven,et al.  Lack of genotoxicity of tamoxifen in human endometrium. , 1996, Cancer research.

[320]  M. Lippman,et al.  The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. , 1976, Cancer research.

[321]  A. Feinstein,et al.  NECROPSY DIAGNOSIS OF ENDOMETRIAL CANCER AND DETECTION-BIAS IN CASE/CONTROL STUDIES , 1981, The Lancet.

[322]  W. Castelli,et al.  Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. , 1988, The Canadian journal of cardiology.

[323]  S. Venitt,et al.  Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. , 1992, Carcinogenesis.

[324]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[325]  R. Higgs,et al.  Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. , 1996, The Journal of pharmacology and experimental therapeutics.

[326]  H. Wiseman Tamoxifen as an antioxidant and cardioprotectant. , 1995, Biochemical Society symposium.

[327]  J. Simard,et al.  Characterization of the effects of the novel non‐steroidal antiestrogen EM‐800 on basal and estrogen‐induced proliferation of T‐47D, ZR‐75‐1 and MCF‐7 human breast cancer cells in vitro , 1997, International journal of cancer.

[328]  A. Hart,et al.  Tamoxifen, serum lipoproteins and cardiovascular risk. , 1988, British Journal of Cancer.

[329]  V. Jordan,et al.  Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. , 1983, Endocrinology.

[330]  V. Jordan,et al.  Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. , 1994, Cancer letters.

[331]  M. Parker,et al.  Assignment of estradiol receptor gene to mouse chromosome 10. , 1988, Journal of steroid biochemistry.

[332]  Nils Wilking,et al.  ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS , 1989, The Lancet.

[333]  U. Eppenberger,et al.  Pharmacologic and Biologic Properties of Droloxifene, A New Antiestrogen , 1991, American journal of clinical oncology.

[334]  C. Osborne,et al.  Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. , 1985, Cancer research.

[335]  B. Katzenellenbogen,et al.  Editorial: A New Actor in the Estrogen Receptor Drama-Enter ER-β. , 1997, Endocrinology.

[336]  M. Sato,et al.  Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. , 1996, Endocrinology.

[337]  J. Direnzo,et al.  p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[338]  N. Knebel,et al.  1‐(Aminoalkyl)‐2‐phenylindoles as Novel Pure Estrogen Antagonists. , 1991 .

[339]  I. Taylor,et al.  Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. , 1983, Cancer research.

[340]  R. Gupta,et al.  Tissue distribution and pharmacokinetics of centchroman. A new nonsteroidal postcoital contraceptive agent and its 7-desmethyl metabolite in female rats after a single oral dose. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[341]  V. Jordan,et al.  Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. , 1991, Journal of the National Cancer Institute.

[342]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[343]  V. Jordan,et al.  Geometric isomers of substituted triphenylethylenes and antiestrogen action. , 1981, Endocrinology.

[344]  A. Munck,et al.  Phosphorylation of steroid hormone receptors. , 1992, Endocrine reviews.

[345]  T. Hirose,et al.  Interaction of DP-TAT-59, an active metabolite of new triphenylethylene-derivative (TAT-59), with estrogen receptors , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[346]  B. O’Malley,et al.  Steroid receptor family: structure and functions. , 1990, Endocrine reviews.

[347]  P. Mullen Immunopharmacological considerations in Reye's syndrome: a possible xenobiotic initiated disorder? , 1978, Biochemical pharmacology.

[348]  J. Massagué Receptors for the TGF-β family , 1992, Cell.

[349]  N. Knebel,et al.  1-(aminoalkyl)-2-phenylindoles as novel pure estrogen antagonists. , 1990, Journal of medicinal chemistry.

[350]  V. Jordan,et al.  Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus , 1982, Molecular and Cellular Endocrinology.

[351]  B. Haynes,et al.  Metabolism of the 4-iodo derivative of tamoxifen by isolated rat hepatocytes. Demonstration that the iodine atom reduces metabolic conversion and identification of four metabolites. , 1990, Biochemical pharmacology.

[352]  S. Fawell,et al.  Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[353]  Masatoshi Hagiwara,et al.  Phosphorylated CREB binds specifically to the nuclear protein CBP , 1993, Nature.

[354]  A. Wakeling,et al.  Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. , 1993, The Journal of endocrinology.

[355]  Mueller Gc,et al.  Studies on the mechanism of action of estrogens. , 1958, Recent progress in hormone research.

[356]  H. Stewart The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. , 1992, Journal of the National Cancer Institute. Monographs.

[357]  L. Kuller,et al.  Coronary heart disease mortality and adjuvant tamoxifen therapy. , 1997, Journal of the National Cancer Institute.

[358]  L. Kangas,et al.  Review of the pharmacological properties of toremifene. , 1990, Journal of steroid biochemistry.

[359]  G. Martin,et al.  Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.

[360]  M. Parker,et al.  Structure and Function of the Estrogen Receptor , 1993, Annals of the New York Academy of Sciences.

[361]  V. Jordan,et al.  Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor. , 1983, Journal of steroid biochemistry.

[362]  A. Philips,et al.  Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. , 1993, The Journal of biological chemistry.

[363]  M. Tzukerman,et al.  Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.

[364]  Jordan Vc Tamoxifen for breast cancer prevention , 1995 .

[365]  Stanley Boyd,et al.  Oophorectomy for Cancer of the Breast , 1900, The Hospital.

[366]  P. Chambon,et al.  Localisation of the oestradiol‐binding and putative DNA‐binding domains of the human oestrogen receptor. , 1986, The EMBO journal.

[367]  Y. Dragan,et al.  Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. , 1995, Cancer research.

[368]  P. Chambon,et al.  The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer , 1988, Cell.

[369]  B. Katzenellenbogen,et al.  Different Regions in Activation Function-1 of the Human Estrogen Receptor Required for Antiestrogen- and Estradiol-dependent Transcription Activation* , 1996, The Journal of Biological Chemistry.

[370]  A. Howell,et al.  Epidermal and transforming growth factor alpha in patients with breast tumours. , 1989, British Journal of Cancer.

[371]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[372]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[373]  A. Brinkmann,et al.  Steroid hormone receptor phosphorylation: is there a physiological role? , 1994, Molecular and Cellular Endocrinology.

[374]  L. Rutqvist,et al.  Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. , 1993, Journal of the National Cancer Institute.

[375]  Michael R. Green,et al.  Nuclear protein CBP is a coactivator for the transcription factor CREB , 1994, Nature.

[376]  R. Turner,et al.  The effects of raloxifene on tibia histomorphometry in ovariectomized rats. , 1994, Endocrinology.

[377]  D. Machin,et al.  Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. , 1997, Journal of the National Cancer Institute.

[378]  K. Jervell,et al.  Studies on the mechanism of action of estrogens. , 1958, Recent progress in hormone research.

[379]  V. Jordan,et al.  Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. , 1990, European journal of cancer.

[380]  A. Kauppila,et al.  Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. , 1995, Gynecologic oncology.

[381]  P. Satyaswaroop,et al.  Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. , 1984, Cancer research.

[382]  D. Hayes,et al.  Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[383]  J. Sherman,et al.  Tamoxifen and Prevention of Breast Cancer , 1998, Toxicology and industrial health.

[384]  S. Robinson,et al.  Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. , 1988, Cancer research.

[385]  B. Katzenellenbogen,et al.  Antiestrogens and antiestrogen metabolites: preparation of tritium-labeled (+/-)-cis-3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxyl]-1,2-propanediol (U-23469) and characterization and synthesis of a biologically important metabolite. , 1979, Journal of medicinal chemistry.

[386]  I. Taylor,et al.  Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. , 1983, European journal of cancer & clinical oncology.

[387]  E Ruoslahti,et al.  A 60-kD protein mediates the binding of transforming growth factor-beta to cell surface and extracellular matrix proteoglycans , 1993, The Journal of cell biology.

[388]  R. Sutherland,et al.  Tamoxifen stimulation of human breast cancer cell proliferation in vitro: a possible model for tamoxifen tumour flare. , 1984, European journal of cancer & clinical oncology.

[389]  C. Christiansen,et al.  EFFECTS OF RALOXIFENE ON BONE MINERAL DENSITY, SERUM CHOLESTEROL CONCENTRATIONS, AND UTERINE ENDOMETRIUM IN POSTMENOPAUSAL WOMEN , 1998 .

[390]  G. T. Budd,et al.  Estrogen receptor mutations in tamoxifen-resistant breast cancer. , 1994, Cancer research.

[391]  W. McGuire,et al.  Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[392]  J. Paliwal,et al.  Centchroman: a new non-steroidal oral contraceptive in human milk. , 1995, Contraception.

[393]  M. Sato,et al.  Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[394]  V. Jordan,et al.  Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro. , 1988, Endocrinology.

[395]  R Clarke,et al.  Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[396]  S. Neidle,et al.  A molecular modeling study of the interactions between the antiestrogen drug tamoxifen and several derivatives, and the calcium-binding protein calmodulin. , 1992, Journal of medicinal chemistry.

[397]  J. Gorski,et al.  Perturbations in the model of estrogen receptor regulation of gene expression. , 1993, Biology of reproduction.

[398]  P. Ravdin,et al.  Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. , 1988, Cancer research.

[399]  Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. , 1996 .

[400]  ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh , 1987, The Lancet.

[401]  P. Chambon,et al.  The transcriptional activation function located in the hormone‐binding domain of the human oestrogen receptor is not encoded in a single exon. , 1989, The EMBO journal.

[402]  K. Hemminki,et al.  Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. , 1996, Cancer research.

[403]  I. Frantz,et al.  Effects of MER-29 on the intermediary metabolism of cholesterol. , 1960, Progress in cardiovascular diseases.

[404]  M. Sporn,et al.  Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. , 1996, Journal of the National Cancer Institute.

[405]  H C Pitot,et al.  Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen. , 1996, Cancer research.

[406]  J. Massagué,et al.  Evidence for the involvement of protein kinase activity in transforming growth factor-beta signal transduction , 1992, Molecular and cellular biology.

[407]  M. Sporn,et al.  Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. , 1990, British Journal of Cancer.

[408]  V. Jordan,et al.  Endometrial carcinoma and tamoxifen: clearing up a controversy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[409]  L. Lerner HORMONE ANTAGONISTS: INHIBITORS OF SPECIFIC ACTIVITIES OF ESTROGEN AND ANDROGEN. , 1964, Recent progress in hormone research.

[410]  N. Normanno,et al.  Regulation by Estrogen through the 5′-Flanking Region of the Transforming Growth Factor α Gene , 1991 .

[411]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.

[412]  C. Klinge,et al.  Dissociation of 4-hydroxytamoxifen, but not estradiol or tamoxifen aziridine, from the estrogen receptor as the receptor binds estrogen response element DNA , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[413]  D. Thompson,et al.  Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. , 1995, Endocrinology.

[414]  P. Webb,et al.  Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. , 1995, Molecular endocrinology.

[415]  V. Jordan,et al.  Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. , 1989, Cancer research.

[416]  S. Fawell,et al.  Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. , 1993, Molecular endocrinology.

[417]  P Argos,et al.  The chicken oestrogen receptor sequence: homology with v‐erbA and the human oestrogen and glucocorticoid receptors. , 1986, The EMBO journal.

[418]  M. Dowsett,et al.  Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration , 1993, The Lancet.

[419]  P. Goss,et al.  Current perspectives on aromatase inhibitors in breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[420]  V. Jordan,et al.  Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. , 1996, British Journal of Cancer.

[421]  Jack Cuzick,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women , 1988 .

[422]  A. Wakeling,et al.  Effects of a non-steroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones. , 1994, The Journal of endocrinology.

[423]  D. Machin,et al.  Re: Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast Cancer , 1997 .

[424]  V. Jordan,et al.  Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. , 1984, Molecular pharmacology.

[425]  J. Simard,et al.  (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. , 1997, Journal of medicinal chemistry.

[426]  I. White,et al.  Effect of tamoxifen feeding on metabolic activation of tamoxifen by the liver of the rhesus monkey: does liver accumulation of inhibitory metabolites protect from tamoxifen-dependent genotoxicity and cancer? , 1996, Carcinogenesis.

[427]  V. Jordan,et al.  Should adjuvant tamoxifen therapy be stopped at 5 years? , 1996, The cancer journal from Scientific American.

[428]  D. Sömjen,et al.  Stimulation of creatine kinase specific activity in human osteoblast and endometrial cells by estrogens and anti-estrogens and its modulation by calciotropic hormones. , 1996, The Journal of endocrinology.

[429]  V. Jordan,et al.  Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. , 1990, Cancer research.

[430]  B. Katzenellenbogen,et al.  Synergistic activation of estrogen receptor-mediated transcription by estradiol and protein kinase activators. , 1993, Molecular endocrinology.

[431]  P. Chambon,et al.  Cooperation of proto‐signals for nuclear accumulation of estrogen and progesterone receptors. , 1992, The EMBO journal.

[432]  F. Gannon,et al.  Evidence for a previously unidentified upstream exon in the human oestrogen receptor gene. , 1991, Journal of molecular endocrinology.

[433]  K. Korach,et al.  The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. , 1991, Endocrinology.

[434]  P. Chambon,et al.  Activation of the ovalbumin gene by the estrogen receptor involves the Fos-Jun complex , 1990, Cell.

[435]  V. Jordan,et al.  Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. , 1998, British Journal of Cancer.

[436]  M. Taskinen,et al.  Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[437]  G. Leclercq,et al.  Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. , 1989, Journal of medicinal chemistry.

[438]  V. Jordan,et al.  Targeted anti-estrogens to treat and prevent diseases in women. , 1996, Molecular medicine today.

[439]  E. Hodgson,et al.  Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[440]  D. Wolf,et al.  A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. , 1995, Molecular endocrinology.

[441]  Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. , 1994, Molecular endocrinology.

[442]  W. Welshons,et al.  Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. , 1987, European journal of cancer & clinical oncology.

[443]  V. Jordan,et al.  Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action. , 1978, Journal of toxicology and environmental health.

[444]  I. Weinstein,et al.  Inhibition of protein kinase C by tamoxifen. , 1985, Cancer research.

[445]  M. Rowlands,et al.  Evidence that tamoxifen binds to calmodulin in a conformation different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues. , 1994, Biochemical pharmacology.

[446]  A. Howell,et al.  Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. , 1994, Cancer research.

[447]  C. Blomqvist,et al.  Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. , 1997, British Journal of Cancer.

[448]  C. Labrie,et al.  Inhibitory effect of the novel anti‐estrogen EM‐800 and medroxyprogesterone acetate on estrone‐stimulated growth of dimethylbenz[a]anthracene‐induced mammary carcinoma in rats , 1997, International journal of cancer.

[449]  Y. Yamasaki,et al.  Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. , 1994, The Journal of biological chemistry.

[450]  E. Jensen,et al.  Fate of Steroid Estrogens in Target Tissues1 , 1960 .

[451]  D. Ingram Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer. , 1990, The Australian and New Zealand journal of surgery.

[452]  V. Jordan,et al.  Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture. , 1989, European journal of cancer & clinical oncology.

[453]  E. Dodds,et al.  Œstrogenic Activity of p-Hydroxy Propenyl Benzene (Anol) , 1937, Nature.

[454]  R. Peto,et al.  Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. , 1989, The New England journal of medicine.

[455]  A. Scanu Lipoprotein(a). A genetic risk factor for premature coronary heart disease. , 1992, JAMA.

[456]  A. Wakeling,et al.  Steroidal pure antioestrogens. , 1987, The Journal of endocrinology.

[457]  B. Katzenellenbogen,et al.  Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. , 1987, Cancer research.

[458]  R. Sutherland,et al.  Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. , 1989, Cancer research.

[459]  H W Cole,et al.  Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. , 1997, Journal of medicinal chemistry.

[460]  G. Teutsch,et al.  RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[461]  T. Stukel,et al.  Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. , 1992, Cancer Research.

[462]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[463]  R. Bigsby,et al.  The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo. , 1997, Endocrinology.

[464]  P. Stern,et al.  Effects of the antiestrogens tamoxifen and clomiphene on bone resorption in vitro. , 1986, Endocrinology.

[465]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.

[466]  R. Derynck,et al.  Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. , 1993, Science.

[467]  G. Teutsch,et al.  RU 58668: Further in vitro and in vivo pharmacological data related to its antitumoral activity , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[468]  Biological Activities of Steroids in Relation to Cancer , 1961, Pediatrics.

[469]  B. Katzenellenbogen,et al.  Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: limitations to the interpretation of experiments characterizing the activity of individual isomers. , 1985, Journal of steroid biochemistry.

[470]  I. Kawamura,et al.  The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells. , 1994, Anticancer research.

[471]  S. Shafie Estrogen and the growth of breast cancer: new evidence suggests indirect action. , 1980, Science.

[472]  M. Green,et al.  Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[473]  W. McGuire,et al.  Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[474]  A. Parkinson,et al.  Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. , 1994, Carcinogenesis.

[475]  D. Williams The estrogen receptor: a minireview. , 1974, Life sciences.

[476]  G. Williams,et al.  The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. , 1993, Carcinogenesis.

[477]  D. Salomon,et al.  Transforming growth factors in human breast cancer. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[478]  E. Dodds,et al.  Synthetic Œstrogenic Agents without the Phenanthrene Nucleus , 1936, Nature.

[479]  C. Redmond,et al.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[480]  C. D. Jones,et al.  Antagonism of estrogen action with a new benzothiophene derived antiestrogen. , 1983, Life sciences.

[481]  A. Mahfoudi,et al.  Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[482]  D. Wolf,et al.  Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. , 1991, British Journal of Cancer.

[483]  J. Gorski,et al.  Remodeling the estrogen receptor model , 1984, Molecular and Cellular Endocrinology.

[484]  M. Parker,et al.  The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. , 1993, Journal of cell science.

[485]  J. Massagué,et al.  Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors , 1993, Cell.

[486]  S. Ray,et al.  Antifertility agents. 12. Structure-activity relationship of 3,4-diphenylchromenes and -chromans. , 1976, Journal of medicinal chemistry.

[487]  D. DeMets,et al.  Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. , 1991, Annals of internal medicine.

[488]  Y. Dragan,et al.  Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. , 1994, Cancer research.

[489]  J. Wolter,et al.  Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. , 1990, The Journal of clinical endocrinology and metabolism.

[490]  C. Osborne,et al.  Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. , 1983, Cancer research.

[491]  J. Gorski,et al.  Estrogen receptor binding to a DNA response element in vitro is not dependent upon estradiol. , 1990, Biochemistry.

[492]  M. Morrow,et al.  Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. , 1993, Archives of surgery.

[493]  V. Jordan,et al.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.

[494]  M. Rowlands,et al.  Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. , 1990, Biochemical pharmacology.

[495]  A. deFazio,et al.  Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. , 1995, Molecular endocrinology.

[496]  M. Fernö,et al.  Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. , 1992, Acta oncologica.

[497]  R. Gupta,et al.  Pharmacokinetics of centchroman in healthy female subjects after oral administration. , 1995, Contraception.

[498]  V. Jordan,et al.  Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. , 1989, European journal of cancer & clinical oncology.

[499]  T. Orton,et al.  Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. , 1993, Cancer research.

[500]  E. di Salle,et al.  Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. , 1990, Journal of steroid biochemistry.

[501]  R. Weigel,et al.  Identification of ERF-1 as a member of the AP2 transcription factor family. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[502]  B. Katzenellenbogen,et al.  Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[503]  M. Thangaraju,et al.  Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer , 1994, Cancer.

[504]  R. Gray,et al.  Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. , 1996, Journal of the National Cancer Institute.

[505]  V. Jordan,et al.  Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro. , 1990, Molecular pharmacology.

[506]  B. Vennström,et al.  The sound of silence , 1995, Nature.

[507]  C. Welsch Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. , 1985, Cancer research.

[508]  N. Koszewski,et al.  Estrogen receptor phosphorylation. Hormonal dependence and consequence on specific DNA binding. , 1992, The Journal of biological chemistry.

[509]  T. Powles,et al.  A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. , 1989, British Journal of Cancer.

[510]  B. S. Setty,et al.  Biological profile of Centchroman--a new post-coital contraceptive. , 1977, Indian journal of experimental biology.

[511]  R. Lurie,et al.  A Realistic Clinical Perspective of Tamoxifen and Endometrial Carcinogenesis , 1996 .

[512]  M. Morrow,et al.  Should clinicians be concerned about the carcinogenic potential of tamoxifen? , 1994, European journal of cancer.

[513]  A. Wakeling,et al.  Novel steroidal pure antiestrogens , 1989, Steroids.

[514]  D. Hanahan,et al.  The metabolic pattern of C14-diethylstilbestrol. , 1953, Endocrinology.

[515]  J. Loscalzo,et al.  Lipoprotein(a). A unique risk factor for atherothrombotic disease. , 1990, Arteriosclerosis.

[516]  T. Kubota,et al.  Antitumor effect of triphenylethylene derivative (TAT‐59) against human breast carcinoma xenografts in nude mice , 1992, Journal of surgical oncology.

[517]  K. Pollow,et al.  Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients , 1991, American journal of clinical oncology.